Prgf Treatment In Sequelae Of Adenovirus Conjunctivitis

Fernandez Vega University Institute - Eye Surface Unit  ( IUFV) Oviedo-Spain

This retrospective study included patients of the consultation of IUFV (Fernández-Vega University Institute) Eye Surface Unit between 2012 and 2013, with no response from previous treatments (standard: artificial tears, corticosteroids, cyclosporine, autologous serum) and presence of SAC (sub-epithelial infiltrates). The treatment was PRGF eye drops 4 times / day ± standard therapy with or without other medications. Primary endpoint was evaluate the resolution time of sub epithelial infiltrates. Other outcome measures including Best Corrected Visual Acuity (BCVA) and intraocular pressure (IOP). The influence of some patients’ clinical variables on results was assessed. Safety assessment was also performed reporting the adverse events.

Forteen eyes in a total of twenty eight patients were evaluated,, previous time with sub-epithelial infiltrates was  10.1 ± 13.8 (0.5-36) months, initial BCVA was  0.77 ± 0.16 (0.2-0.9) Logmar a. The patients needs 2.07 ± 0.6 (1-3) PRGF cycles (1 cycle = 6 weeks) and the treatment time with PRGF was 11.4 ± 6.7 (2.5-27) Months. Ninety percent of patients continued with their standard therapy plus PRGF eye drops 4 times / day. Twenty four patients (86%) resolved sub-epithelial infiltrates, follow up time without regrowth was 19.1 ± 12.8 (2.3-40.5) months. BCVA has a statistical significant improve 0.95 ( 0.0 - 0.09) (p< 0.01) Logmar , and no statistical change in IOP. No Adverse Event with the use of PRGF in any case

PRGF eye-drops could be a effective therapeutic option for patients with sub epithelial infiltrate because sequelae of adenovirus, improving visual acuity, maintaining IOP and safe in its use.